Moving into the next era of PET myocardial perfusion imaging: introduction of novel 18 F-labeled tracers

Rudolf A. Werner, Xinyu Chen, Steven P. Rowe, Constantin Lapa, Mehrbod S. Javadi, Takahiro Higuchi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The heart failure epidemic continues to rise with coronary artery disease as one of its main causes. Novel concepts for risk stratification to guide the referring cardiologist towards revascularization procedures are of significant value. Myocardial perfusion imaging using single-photon emission computed tomography (SPECT) agents has demonstrated high accuracy for the detection of clinically relevant stenoses. With positron emission tomography (PET) becoming more widely available, mainly due to its diagnostic performance in oncology, perfusion imaging with that modality is more practical than in the past and overcomes existing limitations of SPECT MPI. Advantages of PET include more reliable quantification of absolute myocardial blood flow, the routine use of computed tomography for attenuation correction, a higher spatiotemporal resolution and a higher count sensitivity. Current PET radiotracers such as rubidium-82 (half-life, 76 s), oxygen-15 water (2 min) or nitrogen-13 ammonia (10 min) are labeled with radionuclides with very short half-lives, necessitating that stress imaging is performed under pharmacological vasodilator stress instead of exercise testing. However, with the introduction of novel 18 F-labeled MPI PET radiotracers (half-life, 110 min), the intrinsic advantages of PET can be combined with exercise testing. Additional advantages of those radiotracers include, but are not limited to: potentially improved cost-effectiveness due to the use of pre-existing delivery systems and superior imaging qualities, mainly due to the shortest positron range among available PET MPI probes. In the present review, widely used PET MPI radiotracers will be reviewed and potential novel 18 F-labeled perfusion radiotracers will be discussed.

Original languageEnglish
Pages (from-to)569-577
Number of pages9
JournalInternational Journal of Cardiovascular Imaging
Volume35
Issue number3
DOIs
Publication statusPublished - Mar 1 2019
Externally publishedYes

Fingerprint

Myocardial Perfusion Imaging
Positron-Emission Tomography
Single-Photon Emission-Computed Tomography
Half-Life
Exercise
Rubidium
Perfusion Imaging
Vasodilator Agents
Ammonia
Radioisotopes
Cost-Benefit Analysis
Coronary Artery Disease
Pathologic Constriction
Nitrogen
Heart Failure
Perfusion
Tomography
Pharmacology
Electrons
Oxygen

Keywords

  • F-FBnTP
  • F-flurpiridaz
  • Coronary artery disease
  • Myocardial perfusion imaging
  • Positron emission tomography
  • Precision medicine

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Moving into the next era of PET myocardial perfusion imaging : introduction of novel 18 F-labeled tracers. / Werner, Rudolf A.; Chen, Xinyu; Rowe, Steven P.; Lapa, Constantin; Javadi, Mehrbod S.; Higuchi, Takahiro.

In: International Journal of Cardiovascular Imaging, Vol. 35, No. 3, 01.03.2019, p. 569-577.

Research output: Contribution to journalReview article

Werner, Rudolf A. ; Chen, Xinyu ; Rowe, Steven P. ; Lapa, Constantin ; Javadi, Mehrbod S. ; Higuchi, Takahiro. / Moving into the next era of PET myocardial perfusion imaging : introduction of novel 18 F-labeled tracers. In: International Journal of Cardiovascular Imaging. 2019 ; Vol. 35, No. 3. pp. 569-577.
@article{ea8baa6248fb4874b99489731be607d1,
title = "Moving into the next era of PET myocardial perfusion imaging: introduction of novel 18 F-labeled tracers",
abstract = "The heart failure epidemic continues to rise with coronary artery disease as one of its main causes. Novel concepts for risk stratification to guide the referring cardiologist towards revascularization procedures are of significant value. Myocardial perfusion imaging using single-photon emission computed tomography (SPECT) agents has demonstrated high accuracy for the detection of clinically relevant stenoses. With positron emission tomography (PET) becoming more widely available, mainly due to its diagnostic performance in oncology, perfusion imaging with that modality is more practical than in the past and overcomes existing limitations of SPECT MPI. Advantages of PET include more reliable quantification of absolute myocardial blood flow, the routine use of computed tomography for attenuation correction, a higher spatiotemporal resolution and a higher count sensitivity. Current PET radiotracers such as rubidium-82 (half-life, 76 s), oxygen-15 water (2 min) or nitrogen-13 ammonia (10 min) are labeled with radionuclides with very short half-lives, necessitating that stress imaging is performed under pharmacological vasodilator stress instead of exercise testing. However, with the introduction of novel 18 F-labeled MPI PET radiotracers (half-life, 110 min), the intrinsic advantages of PET can be combined with exercise testing. Additional advantages of those radiotracers include, but are not limited to: potentially improved cost-effectiveness due to the use of pre-existing delivery systems and superior imaging qualities, mainly due to the shortest positron range among available PET MPI probes. In the present review, widely used PET MPI radiotracers will be reviewed and potential novel 18 F-labeled perfusion radiotracers will be discussed.",
keywords = "F-FBnTP, F-flurpiridaz, Coronary artery disease, Myocardial perfusion imaging, Positron emission tomography, Precision medicine",
author = "Werner, {Rudolf A.} and Xinyu Chen and Rowe, {Steven P.} and Constantin Lapa and Javadi, {Mehrbod S.} and Takahiro Higuchi",
year = "2019",
month = "3",
day = "1",
doi = "10.1007/s10554-018-1469-z",
language = "English",
volume = "35",
pages = "569--577",
journal = "International Journal of Cardiovascular Imaging",
issn = "0167-9899",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Moving into the next era of PET myocardial perfusion imaging

T2 - introduction of novel 18 F-labeled tracers

AU - Werner, Rudolf A.

AU - Chen, Xinyu

AU - Rowe, Steven P.

AU - Lapa, Constantin

AU - Javadi, Mehrbod S.

AU - Higuchi, Takahiro

PY - 2019/3/1

Y1 - 2019/3/1

N2 - The heart failure epidemic continues to rise with coronary artery disease as one of its main causes. Novel concepts for risk stratification to guide the referring cardiologist towards revascularization procedures are of significant value. Myocardial perfusion imaging using single-photon emission computed tomography (SPECT) agents has demonstrated high accuracy for the detection of clinically relevant stenoses. With positron emission tomography (PET) becoming more widely available, mainly due to its diagnostic performance in oncology, perfusion imaging with that modality is more practical than in the past and overcomes existing limitations of SPECT MPI. Advantages of PET include more reliable quantification of absolute myocardial blood flow, the routine use of computed tomography for attenuation correction, a higher spatiotemporal resolution and a higher count sensitivity. Current PET radiotracers such as rubidium-82 (half-life, 76 s), oxygen-15 water (2 min) or nitrogen-13 ammonia (10 min) are labeled with radionuclides with very short half-lives, necessitating that stress imaging is performed under pharmacological vasodilator stress instead of exercise testing. However, with the introduction of novel 18 F-labeled MPI PET radiotracers (half-life, 110 min), the intrinsic advantages of PET can be combined with exercise testing. Additional advantages of those radiotracers include, but are not limited to: potentially improved cost-effectiveness due to the use of pre-existing delivery systems and superior imaging qualities, mainly due to the shortest positron range among available PET MPI probes. In the present review, widely used PET MPI radiotracers will be reviewed and potential novel 18 F-labeled perfusion radiotracers will be discussed.

AB - The heart failure epidemic continues to rise with coronary artery disease as one of its main causes. Novel concepts for risk stratification to guide the referring cardiologist towards revascularization procedures are of significant value. Myocardial perfusion imaging using single-photon emission computed tomography (SPECT) agents has demonstrated high accuracy for the detection of clinically relevant stenoses. With positron emission tomography (PET) becoming more widely available, mainly due to its diagnostic performance in oncology, perfusion imaging with that modality is more practical than in the past and overcomes existing limitations of SPECT MPI. Advantages of PET include more reliable quantification of absolute myocardial blood flow, the routine use of computed tomography for attenuation correction, a higher spatiotemporal resolution and a higher count sensitivity. Current PET radiotracers such as rubidium-82 (half-life, 76 s), oxygen-15 water (2 min) or nitrogen-13 ammonia (10 min) are labeled with radionuclides with very short half-lives, necessitating that stress imaging is performed under pharmacological vasodilator stress instead of exercise testing. However, with the introduction of novel 18 F-labeled MPI PET radiotracers (half-life, 110 min), the intrinsic advantages of PET can be combined with exercise testing. Additional advantages of those radiotracers include, but are not limited to: potentially improved cost-effectiveness due to the use of pre-existing delivery systems and superior imaging qualities, mainly due to the shortest positron range among available PET MPI probes. In the present review, widely used PET MPI radiotracers will be reviewed and potential novel 18 F-labeled perfusion radiotracers will be discussed.

KW - F-FBnTP

KW - F-flurpiridaz

KW - Coronary artery disease

KW - Myocardial perfusion imaging

KW - Positron emission tomography

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85055455008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055455008&partnerID=8YFLogxK

U2 - 10.1007/s10554-018-1469-z

DO - 10.1007/s10554-018-1469-z

M3 - Review article

C2 - 30334228

AN - SCOPUS:85055455008

VL - 35

SP - 569

EP - 577

JO - International Journal of Cardiovascular Imaging

JF - International Journal of Cardiovascular Imaging

SN - 0167-9899

IS - 3

ER -